Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Gómez Veiga, Francisco
940  Ergebnisse:
Personensuche X
?
1

Intermittent Versus Continuous Androgen Deprivation Therapy..:

Schulman, Claude ; Cornel, Erik ; Matveev, Vsevolod...
European Urology.  69 (2016)  4 - p. 720-727 , 2016
Link: https://doi.org/10.1016/..
 
?
2

Prevention of Bone Metastases in Patients with High-risk No..:

Wirth, Manfred ; Tammela, Teuvo ; Cicalese, Virgilio...
European Urology.  67 (2015)  3 - p. 482-491 , 2015
Link: https://doi.org/10.1016/..
 
?
3

Automated Bone Scan Index as an Imaging Biomarker to Predic..:

Reza, Mariana ; Wirth, Manfred ; Tammela, Teuvo...
European Urology Oncology.  4 (2021)  1 - p. 49-55 , 2021
Link: https://doi.org/10.1016/..
 
?
4

Report of a consensus meeting on focal low dose rate brachy..:

Langley, Stephen ; Ahmed, Hashim U. ; Al‐Qaisieh, Bashar...
BJU International.  109 (2012)  s1 - p. 7-16 , 2012
Link: https://doi.org/10.1111/..
 
?
5

A Phase 2 Randomized Open-label Study of Oral Darolutamide ..:

Tombal, Bertrand F. ; Gomez-Veiga, Francisco ; Gomez-Ferrer, Alvaro...
European Urology Oncology.  , 2024
Link: https://doi.org/10.1016/..
 
?
6

Clinical Outcomes of Enzalutamide in Metastatic Hormone-sen..:

Gomez-Veiga, Francisco ; Szmulewitz, Russell Z. ; Holzbeierlein, Jeffrey...
European Urology Oncology.  7 (2024)  4 - p. 860-869 , 2024
Link: https://doi.org/10.1016/..
 
?
7

The Efficacy of Enzalutamide plus Androgen Deprivation Ther..:

Armstrong, Andrew J. ; Iguchi, Taro ; Azad, Arun A....
European Urology.  84 (2023)  2 - p. 229-241 , 2023
Link: https://doi.org/10.1016/..
 
?
8

Hyperthermic Mitomycin C in Intermediate-risk Non–muscle-in..:

Angulo, Javier C. ; Álvarez-Ossorio, José L. ; Domínguez-Escrig, José L....
European Urology Oncology.  6 (2023)  1 - p. 58-66 , 2023
Link: https://doi.org/10.1016/..
 
?
9

Real-World Safety and Efficacy Outcomes with Abiraterone Ac..:

Bjartell, Anders ; Lumen, Nicolaas ; Maroto, Pablo...
Targeted Oncology.  16 (2021)  3 - p. 357-367 , 2021
Link: https://doi.org/10.1007/..
 
?
10

Mapping the Patient-Oriented Prostate Utility Scale From th..:

Zamora, Víctor ; Garin, Olatz ; Pardo, Yolanda...
Value in Health.  24 (2021)  11 - p. 1676-1685 , 2021
Link: https://doi.org/10.1016/..
 
?
11

Efficacy of enzalutamide in subgroups of men with metastati..:

Azad, Arun A. ; Armstrong, Andrew J. ; Alcaraz, Antonio...
Prostate Cancer and Prostatic Diseases.  25 (2021)  2 - p. 274-282 , 2021
Link: https://doi.org/10.1038/..
 
?
12

Real-World Outcomes in First-Line Treatment of Metastatic C..:

Chowdhury, Simon ; Bjartell, Anders ; Lumen, Nicolaas...
Targeted Oncology.  15 (2020)  3 - p. 301-315 , 2020
Link: https://doi.org/10.1007/..
 
?
13

Expert opinion on first-line therapy in the treatment of ca..:

Maroto, Pablo ; Solsona, Eduardo ; Gallardo, Enrique...
Critical Reviews in Oncology/Hematology.  100 (2016)  - p. 127-136 , 2016
Link: https://doi.org/10.1016/..
 
?
14

Developments in urologic oncology "OncoForum": The best of ..:

Gómez-Veiga, Francisco ; Alcaraz-Asensio, Antonio ; Burgos-Revilla, Javier.
Actas Urológicas Españolas (English Edition).  40 (2016)  6 - p. 361-369 , 2016
Link: https://doi.org/10.1016/..
 
?
15

Intermittent Versus Continuous Androgen Deprivation Therapy..:

Schulman, Claude ; Cornel, Erik ; Matveev, Vsevolod...
0302-2838.  , 2016
Link: https://trepo.tuni.fi/ha..
 
1-15